Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Merck KGaA logo

OTC · MKKGY

Merck KGaA

Healthcare · Drug Manufacturers - Specialty & Generic

$33.68

Up+$0.01 (+0.03%)

Updated Oct 31, 2026, 5:07 AM

SID Score

7.9/10

Composite research score

Smart Money

46/100

Neutral

Market cap
61.14B
P/E ratio
17.39
Dividend yield
1.48%
52-week range
$23.73 – $34.19
Volume
51.2K
Avg. volume
155.75K

Price performance · MKKGY

MKKGY price history

1M range · 15 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

MKKGY closed at $32.91 after 15 trading sessions, up 6.60% for the selected period.

Last close
$32.91
Period change
+6.60%
Period low
$30.69
Period high
$33.09
Daily close
View OHLC price history
MKKGY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$32.85$33.10$32.82$32.908551.2K
Oct 21, 2026$32.67$32.741$32.10$32.229118.99K
Oct 20, 2026$32.67$33.12$32.66$33.09140.38K
Oct 19, 2026$32.11$32.56$32.07$32.2785.51K
Oct 16, 2026$32.50$32.53$32.24$32.27120.54K
Oct 15, 2026$32.20$32.202$32.01$32.0755.14K
Oct 14, 2026$31.29$31.67$31.29$31.6282.07K
Oct 13, 2026$31.57$31.57$30.84$30.885110.57K
Oct 12, 2026$31.12$31.12$30.91$30.9970.07K
Oct 9, 2026$30.90$31.11$30.87$31.06138.22K
Oct 8, 2026$30.91$30.92$30.39$30.78117.27K
Oct 7, 2026$31.32$31.496$30.99$31.3771.28K
Oct 6, 2026$31.93$31.93$31.10$31.246186.86K
Oct 5, 2026$30.48$30.71$30.38$30.69107.39K
Oct 2, 2026$30.6065$30.89$30.552$30.87111.41K

Latest MKKGY news

The latest Smart Investors Daily articles mentioning MKKGY.

Stock researchCompany · Overview

MKKGY research

Overview

Company profile and research snapshot.

Company profile

MERCK KGAA SPNS/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$53.96
Implied upside
—
Analysts
11
MKKGY recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 21, 2026DAY BY DAYHold—
Sep 10, 2026BAADER EUROPE / ALPHAVALUEBuy—
Sep 4, 2026EQUITA SIMHold—
Sep 3, 2026JEFFERIESHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Global Bioprocessing Reagent Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, Danaher, Merck KGaA and Sartorius Accelerate AI and Single-Use Systems

Boost ROI via single-use systems, AI optimization and continuous processing to cut capital costs, contamination and downtime while improving yield, scalability and efficiency.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Bioprocessing Reagent Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global bioprocessing reagent market is experiencing rapid expansion, driven by rising biologics production, increased vaccine manufacturing, and continued investment in pharmaceutical

Yahoo · Oct 21, 2026

Global Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the Industry

Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Human Osteoblasts Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global human osteoblasts market is experiencing strong growth, supported by the rising prevalence of bone-related diseases, an expanding geriatric population, and increased investment in regenerative medicine and bone tissue engineering. The market is projected to grow from $35.81 billion in 2025 to $38.68 billion in 2026, representing a compound annual growth

Yahoo · Oct 20, 2026

Merck KGaA (XTRA:MRK) Stock Seems Hard To Call After Its 30% Run

Merck KGaA has enjoyed a solid share price climb over the past year, which puts a spotlight on whether that move is matched by what the business is earning. With fresh deal activity and partnerships in the background, the live question for investors is how well today's valuation lines up with its earnings power. The stock has returned 30.1% over the past year, which makes it important to test whether that gain is grounded in its earnings rather than just sentiment. The planned US$1.3b...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By